Lilly’s Triple-Agonist Retatrutide Delivers Unprecedented Weight Loss, Dramatically Reduces Osteoarthritis Pain in Phase 3 Trial
Eli Lilly and Company announced groundbreaking positive topline results from the Phase 3 TRIUMPH-4 clinical trial, confirming its investigational triple-agonist drug, retatrutide, delivered unprecedented weight loss of up to 28.7% (71.2 lbs) and substantial relief from the pain and functional limitations associated with knee osteoarthritis.
